Identification of Transcriptional Regulators of Immune Evasion Across Cancers: An Alternative Immunotherapeutic Strategy for Cholangiocarcinoma DOI Open Access
Simran Venkatraman, Brinda Balasubramanian, Pornparn Kongpracha

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4197 - 4197

Published: Dec. 17, 2024

Background: Cancer immune evasion is a multifaceted process that synchronizes pro-tumoral infiltration, immunosuppressive inflammation, and inhibitory checkpoint expression (IC). Current immunotherapies combat this issue by reinstating immunosurveillance of tumors; however, it benefits limited patient population. Thus, more effective immunotherapeutic strategy warranted to cater specific populations. This investigation introduces novel via inhibition master regulators (MR-IE). Methods: Samples the TCGA Pan-Cancer Atlas transcriptomic data were subset stratified based on IC estimated cell infiltration. Transcriptomic analysis was conducted unravel pathways associated with process. Transcription factor enrichment survival analyses identify rank candidate MR-IEs per cancer type. Results: Inhibition top-ranking MR-IE cholangiocarcinoma (CCA), MYC, modulated gene protein PD-L1. Moreover, inflammatory markers, IFNA21 CX3CL1, downregulated, anti-tumoral cytokines, IL-18 IL-16, upregulated. Lastly, MYC potentiated fourth-generation anti-folate receptor alpha (FRα) CAR-T therapy against CCA cells. Conclusions: Cumulatively, study highlights promise as potent for treatment offers list type further validation.

Language: Английский

Evolving approaches in advanced gallbladder cancer with complete pathological response using chemo‑immunotherapy: A case report DOI Open Access
Elena Orlandi,

Ilaria Toscani,

Serena Trubini

et al.

Oncology Letters, Journal Year: 2024, Volume and Issue: 28(4)

Published: Aug. 2, 2024

The combination of chemotherapy and immunotherapy for metastatic cholangiocarcinoma (CCA) offers promising improvements in survival response rates beyond traditional treatments. TOPAZ-1 KEYNOTE-966 have demonstrated the efficacy combining (durvalumab pembrolizumab) with chemotherapy, even gallbladder cancer (GBC), a complete rate 2.7% trial. Advanced CCA treated combinations has shown responses influenced by high programmed death-ligand 1 (PD-L1) or Epstein-Barr virus expression. These were enhanced radiotherapy cell death protein (PD-1) blockade. A 62-year-old man was diagnosed unresectable GBC, distant lymphatic metastases, local invasion liver segments 4i 5, colonic hepatic flexure, duodenal bulb, pancreatic head. Immunohistochemical examination revealed poorly differentiated squamous carcinoma, without expression PD-L1. Next generation sequencing mutation ERBB2 R678Q microsatellite stable tumour. patient started chemo-immunotherapy cisplatin-gemcitabine plus durvalumab June 2022. After eight cycles, significant reduction tumour volume markers reported, therapy maintained through November 2023. subsequent computed tomography scans showed further volume, surgical resection performed. Histological examinations confirmed absence residual lymph node metastases. As 2024, no signs disease recurrence. Several reports conversion surgery GBC exist, but data on pre-surgical are limited. Furthermore, pathological confirmation raises several questions regarding need after immunotherapy. Although effective control regression been reported advanced combined anti-cytotoxic T-lymphocyte associated 4 anti-PD-1 agents studies needed to identify reliable predictive biomarkers due unclear associations PD-L1 mutational burden. Overall, treating CCA, especially when tailored specific molecular profiles. treatments may lead novel strategies.

Language: Английский

Citations

0
Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies DOI
Yidan Lou, Yijing Chen, Kaibo Guo

et al.

Biomarkers in Medicine, Journal Year: 2024, Volume and Issue: 18(15-16), P. 703 - 715

Published: Aug. 15, 2024

Biliary tract cancers (BTCs) have rising incidence and mortality rates. Chemotherapy's limited efficacy has led to exploring new treatments like immunotherapy. which offers modest benefits. Moreover, the identification of reliable predictive biomarkers for immune checkpoint therapy in BTCs remains elusive, hindering personalized treatment strategies. This review provides an overview current landscape emerging immunotherapy response BTCs. We discuss incremental benefits combination evolving role managing advanced BTC. Additionally, we highlight need robust optimize outcomes foster a more individualized approach patient care. aim identify promising research avenues strategies enhance therapeutic survival

Language: Английский

Citations

0
Machine Learning Model to Predict Early Recurrence in Patients with Perihilar Cholangiocarcinoma Planned Treatment with Curative Resection: A Multicenter Study DOI Creative Commons
Xiang Wang, Zhi-Peng Liu,

Jiao-Yang Wang

et al.

Journal of Gastrointestinal Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

0
Classification of intrahepatic cholangiocarcinoma DOI
Maria El Homsi, Ahmad Alkhasawneh, Hina Arif‐Tiwari

et al.

Abdominal Radiology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 4, 2024

Language: Английский

Citations

0
Identification of Transcriptional Regulators of Immune Evasion Across Cancers: An Alternative Immunotherapeutic Strategy for Cholangiocarcinoma DOI Open Access
Simran Venkatraman, Brinda Balasubramanian, Pornparn Kongpracha

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4197 - 4197

Published: Dec. 17, 2024

Background: Cancer immune evasion is a multifaceted process that synchronizes pro-tumoral infiltration, immunosuppressive inflammation, and inhibitory checkpoint expression (IC). Current immunotherapies combat this issue by reinstating immunosurveillance of tumors; however, it benefits limited patient population. Thus, more effective immunotherapeutic strategy warranted to cater specific populations. This investigation introduces novel via inhibition master regulators (MR-IE). Methods: Samples the TCGA Pan-Cancer Atlas transcriptomic data were subset stratified based on IC estimated cell infiltration. Transcriptomic analysis was conducted unravel pathways associated with process. Transcription factor enrichment survival analyses identify rank candidate MR-IEs per cancer type. Results: Inhibition top-ranking MR-IE cholangiocarcinoma (CCA), MYC, modulated gene protein PD-L1. Moreover, inflammatory markers, IFNA21 CX3CL1, downregulated, anti-tumoral cytokines, IL-18 IL-16, upregulated. Lastly, MYC potentiated fourth-generation anti-folate receptor alpha (FRα) CAR-T therapy against CCA cells. Conclusions: Cumulatively, study highlights promise as potent for treatment offers list type further validation.

Language: Английский

Citations

0